<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012631</url>
  </required_header>
  <id_info>
    <org_study_id>Losartan-CMR</org_study_id>
    <nct_id>NCT05012631</nct_id>
  </id_info>
  <brief_title>Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease</brief_title>
  <official_title>Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease: A Prospective, Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pilot, phase II, open-label study of the angiotensin II receptor blocker,&#xD;
      losartan, in patients with Sickle Cell Disease (SCD) 6 years or older for 12 months. The&#xD;
      investigators will enroll 24 patients with SCD over the course of 1 year with a goal to&#xD;
      complete all study procedures in 2 years. The short-term goal is to obtain clinical pilot&#xD;
      data regarding the safety and efficacy of losartan in stabilizing or decreasing extracellular&#xD;
      volume fraction (ECV) after 12 months of therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in extracellular volume fraction (ECV) after 1 year of losartan treatment</measure>
    <time_frame>after 1 year of losartan treatment.</time_frame>
    <description>Efficacy of losartan in stabilizing or reducing ECV (diffuse myocardial fibrosis) in SCD after one year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Function</measure>
    <time_frame>after 1 year of losartan treatment.</time_frame>
    <description>Efficacy of losartan in improving diastolic function defined by echocardiographic and tissue Doppler assessment .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Exercise Capacity</measure>
    <time_frame>after 1 year of losartan treatment.</time_frame>
    <description>Efficacy of losartan in improving cardiopulmonary exercise testing (CPET) measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predicting Myocardial Fibrosis</measure>
    <time_frame>At baseline and after one year of losartan treaement</time_frame>
    <description>Explore the performance characteristics of the following serum biomarkers in predicting myocardial fibrosis in patients with SCD: PICP, PIIINP, TGF-β, CTGF, soluble ST2, galectin-3, and NT-proBNP.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Diffuse Myocardial Fibrosis</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral losartan as tablets or oral solution one time daily. The dosing will depend on age and will be based on drug label and dosing used in studies on patients with SCD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan dosing for participants &lt;16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 6 years old or older&#xD;
&#xD;
          2. Diagnosis of HbSS or Sbeta0-thalassemia&#xD;
&#xD;
          3. Ability to cooperate with and undergo CMR without sedation or anesthesia&#xD;
&#xD;
          4. Ability to cooperate with and undergo echocardiogram without sedation or anesthesia&#xD;
&#xD;
          5. Patients who are on a stable dose of sickle cell disease-modifying therapy:&#xD;
             Hydroxyurea, Voxelotor, L-Glutamine, or Crizanlizumab, for 3 months prior to&#xD;
             enrollment will be eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current chronic transfusion therapy. Patients who received a simple transfusion for an&#xD;
             acute event will be eligible 3 months after completion of transfusion&#xD;
&#xD;
          2. SCD genotypes other than specified in inclusion criteria&#xD;
&#xD;
          3. Any contraindication to CMR such as metallic implants&#xD;
&#xD;
          4. Inability to cooperate with CMR or echocardiography imaging&#xD;
&#xD;
          5. Known congenital heart disease&#xD;
&#xD;
          6. Estimated GFR ≤ to 30 mL/min/1.73 m2 by creatinine clearance&#xD;
&#xD;
          7. Pregnant or lactating females or females of child-bearing potential who are unable to&#xD;
             use a medically accepted form of contraception throughout the study&#xD;
&#xD;
          8. Treatment with a renin-angiotensin pathway inhibitor during the 2 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          9. Hypersensitivity to angiotensin receptor II blockers&#xD;
&#xD;
         10. Hyperkalemia (K&gt;5.5 mEq/L) on a non-hemolyzed sample despite low-potassium diet&#xD;
&#xD;
         11. Hepatic dysfunction defined as serum ALT &gt; 5x the upper normal limit for age&#xD;
&#xD;
         12. Current lithium therapy&#xD;
&#xD;
         13. Chronic daily use of NSAID&#xD;
&#xD;
         14. HIV infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Omar Niss, MD</last_name>
    <phone>(513) 803-7545</phone>
    <email>omar.niss@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Pfeiffer</last_name>
    <phone>(513) 803-4977</phone>
    <email>amanda.pfeiffer@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Pfeiffer</last_name>
      <phone>513-803-4977</phone>
      <email>Amanda.Pfeiffer@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Amy Shova</last_name>
      <phone>(513)803-1917</phone>
      <email>Amy.Shova@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Omar Niss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

